Derek J Jonker

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. ncbi request reprint Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007
  2. doi request reprint Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline
    D J Jonker
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Clin Oncol (R Coll Radiol) 23:314-22. 2011
  3. pmc A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    D J Jonker
    Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada
    Ann Oncol 22:1413-9. 2011
  4. doi request reprint Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
    Lillian L Siu
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 31:2477-84. 2013
  5. doi request reprint Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
    Nicole Mittmann
    Health Outcomes and Pharmacoeconomics Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    J Natl Cancer Inst 101:1182-92. 2009
  6. ncbi request reprint Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors
    Nirit Yarom
    Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Ontario, Canada
    Curr Clin Pharmacol 8:81-8. 2013
  7. doi request reprint Quality of life in patients with K-RAS wild-type colorectal cancer: The CO.20 Phase 3 Randomized Trial
    Jolie Ringash
    Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Cancer 120:181-9. 2014
  8. doi request reprint A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
    Rafal Wierzbicki
    Durham Regional Cancer Centre, 1 Hospital Court, Oshawa, ON, L1G 2B9, Canada
    Invest New Drugs 29:167-74. 2011
  9. doi request reprint Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease
    Michael M Vickers
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
    Clin Exp Metastasis 29:123-32. 2012
  10. ncbi request reprint ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report
    Nirit Yarom
    The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Anticancer Res 31:3921-5. 2011

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007
    ..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...
  2. doi request reprint Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline
    D J Jonker
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Clin Oncol (R Coll Radiol) 23:314-22. 2011
    ....
  3. pmc A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    D J Jonker
    Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada
    Ann Oncol 22:1413-9. 2011
    ..This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors...
  4. doi request reprint Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
    Lillian L Siu
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 31:2477-84. 2013
    ..The addition of brivanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has shown encouraging early clinical activity...
  5. doi request reprint Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
    Nicole Mittmann
    Health Outcomes and Pharmacoeconomics Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    J Natl Cancer Inst 101:1182-92. 2009
    ..17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274)...
  6. ncbi request reprint Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors
    Nirit Yarom
    Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Ontario, Canada
    Curr Clin Pharmacol 8:81-8. 2013
    ..Eleven patients had disease control, the single patient who had partial response had N-cadherin positive tumor. Conclusion: ADH-1 is a well tolerated drug with a modest anti tumor effect in tumors which express N-cadherin...
  7. doi request reprint Quality of life in patients with K-RAS wild-type colorectal cancer: The CO.20 Phase 3 Randomized Trial
    Jolie Ringash
    Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    Cancer 120:181-9. 2014
    ..The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo)...
  8. doi request reprint A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
    Rafal Wierzbicki
    Durham Regional Cancer Centre, 1 Hospital Court, Oshawa, ON, L1G 2B9, Canada
    Invest New Drugs 29:167-74. 2011
    ..To determine antitumor activity of cetuximab monotherapy in patients with refractory metastatic colorectal carcinoma (mCRC) with lack of specific membrane immunostaining for the epidermal growth factor receptor (EGFR)...
  9. doi request reprint Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease
    Michael M Vickers
    Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
    Clin Exp Metastasis 29:123-32. 2012
    ..We have further found that an analysis of these five miRs expression levels in primary tumors significantly correlates with the presence of metastatic disease, making this a potential clinically useful prognostic tool...
  10. ncbi request reprint ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report
    Nirit Yarom
    The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
    Anticancer Res 31:3921-5. 2011
    ..This observation merits consideration for prospectively evaluating the efficacy of ADH-1 in patients with cortisol secreting ACC that over express N-cadherin...
  11. doi request reprint Impact of patient selection, disease progression, and adverse events on esophageal cancer outcomes after trimodality therapy
    Sebastien Gilbert
    Division of Thoracic Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada
    Ann Thorac Surg 94:1659-66. 2012
    ..Neoadjuvant chemoradiation followed by surgery (NeoCRT) has been advocated as standard therapy for resectable esophageal cancer. Our objective was to compare oncologic outcomes between NeoCRT and upfront surgical resection (SURG)...
  12. ncbi request reprint The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer
    Nirit Yarom
    Department of Medical Oncology, The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada
    Discov Med 11:95-105. 2011
    ..The anti-EGFR monoclonal antibodies and their predictive biomarkers have taken colon cancer treatment another step closer towards the goal of tailored cancer therapy...
  13. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...